ArticleInternational journal of molecular sciences2019
Legumain Promotes Atherosclerotic Vascular Remodeling.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial.Journal of the American Heart Association · 2020Trial
- Review
- LGMN regulates endothelial-to-mesenchymal transition via the p38 MAPK pathway to promote pulmonary fibrosis.Functional & integrative genomics · 2026Article
- Asparagine endopeptidase cleaves apolipoprotein A1 and accelerates pathogenesis of atherosclerosis.The Journal of clinical investigation · 2025Article
- Asparagine Endopeptidase Inhibition Attenuates Tissue Plasminogen Activator-Induced Brain Hemorrhagic Transformation After Ischemic Stroke.CNS neuroscience & therapeutics · 2025Article
- Light-based 3D bioprinting techniques for illuminating the advances of vascular tissue engineering.Materials today. Bio · 2024Review
- Legumain in cardiovascular diseases.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- Association between atherosclerosis and the development of multi-organ pathologies.SAGE open medicine · 2024Review
- Role of LGMN in tumor development and its progression and connection with the tumor microenvironment.Frontiers in molecular biosciences · 2023Review
- The Mammalian Cysteine Protease Legumain in Health and Disease.International journal of molecular sciences · 2022Review
- C/EBPβ/AEP signaling couples atherosclerosis to the pathogenesis of Alzheimer's disease.Molecular psychiatry · 2022Article
- The Biofabrication of Diseased Artery In Vitro Models.Micromachines · 2022Review
- Progress of Pathogenesis in Pediatric Multifocal Atrial Tachycardia.Frontiers in pediatrics · 2022Review
- Serum Legumain Is Associated with Peripheral Artery Disease in Patients with Type 2 Diabetes.Journal of diabetes research · 2021Article
- Associations of Interleukin 10, Matrix Metallopeptidase 9, and Legumain with Blood Pressure Variability and Neurologic Outcomes in Patients with Ischemic Stroke.International journal of general medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Legumain, a recently discovered cysteine protease, is increased in both carotid plaques and plasma of patients with carotid atherosclerosis. Legumain increases the migration of human monocytes and human umbilical vein endothelial cells (HUVECs). However, the causal relationship between legumain and atherosclerosis formation is not clear. We assessed the expression of legumain in aortic atheromatous plaques and after wire-injury-induced femoral artery neointimal thickening and investigated the effect of chronic legumain infusion on atherogenesis in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.